All products sold by Polar Peptides are intended strictly for research use only and are not intended for human consumption, medical use, diagnostic use, or any other unauthorized use
Gopal Grandhige, MD, FACS, Board-Certified Surgeon Last Reviewed: March 16, 2026 BPC-157 typically begins working within the first one to two weeks, with most patients noticing subtle improvements such as reduced soreness, better digestion, and decreased inflammation during this early phase
While there are a few possible side effects of Tri-Immune injections, they are rare
The FDA says that they would not take action against a compounder for using a Category 1 substance but would consider taking action for those that use Category 2 or 3 substances
We understand that patient comfort is paramount